Advertisement
ALRN Forex Haberleri
Aileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924
Aileron Therapeutics (ALRN) announced Tuesday that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia.
RTTNews
|
818 gün önce
